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Summary  Brucellosis  is  an  ancient  disease  that  still  remains  a  signiﬁcant  threat
to  humans  and  is  typically  linked  to  exposure  to  infected  animals  and/or  consump-
tion  of  unpasteurized  animal  products.  Despite  this  history,  we  have  a  relatively
limited  understanding  of  the  host  characteristics  of  this  disease;  consequently,  fur-
ther  research  is  necessary.  In  this  study,  we  examined  the  humoral  immune  response
in  43  Georgian  individuals  that  had  been  diagnosed  with  brucellosis  3—12  months
before  enrollment  in  the  study,  many  of  whom  still  had  symptoms  after  the  comple-
tion  of  antibiotic  therapy.  In  total,  35  of  43  (83%)  of  the  patients  had  antibodies  that
bound  to  Brucella  lipopolysaccharide  (LPS)  by  COMPELISA,  and  34  of  38  (89%)  patients
had  demonstrable  speciﬁc  antibodies  to  BrucellergeneTM antigens;  the  results  from
hly  correlated  (p  =  0.031,  r  =  0.851).  We  also  studied  the  cellu-the  two  ELISAs  were  hig
lar  immune  responses  in  15  patients.  All  of  the  patients  generated  interferon  (IFN)-
in  response  to  ex  vivo  stimulation  with  Brucella  protein  antigens,  and  the  majority
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of  the  patients  maintained  measurable  humoral  responses  to  both  LPS  and  protein
antigens.  From  this  initial  study,  we  conclude  that  measurement  of  antibody  and  of
cellular  (IFN-) responses  to  brucellergene  OCB  protein  epitopes  may  be  worthy  of
further  investigation  as  an  alternative  or  adjunct  to  current  diagnostics.
dulaziz  University  for  Health  Sciences.  Published  by  Elsevier
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background information  on  the  immune  response
to brucellosis  in  patients  in  Georgia  using  exist-©  2012  King  Saud  Bin  Ab
Ltd.  All  rights  reserved.
Introduction
Brucellosis  is  a  chronic,  debilitating  infection  that
is responsible  for  substantial  morbidity  worldwide
[1]; it  is  caused  by  a  variety  of  Brucella  species,
which are  Gram-negative  coccobacilli  and  intra-
cellular  pathogens.  Brucella  species  are  zoonotic,
and  infections  occur  in  a  wide  variety  of mam-
malian hosts,  including  domestic  livestock,  such  as
cattle, sheep,  goats  and  pigs.  Human  disease  is  typi-
cally linked  to  exposure  to  infected  animals  (such  as
during slaughtering)  or  consumption  of  unpasteur-
ized  animal  products,  such  as  milk  or  cheese  [2].
Patients  often  require  prolonged  antibiotic  therapy,
and relapses  of  infection  can  occur  after  therapy
[3]. Brucella  species  are  also  considered  to  pose
a substantial  threat  as  possible  biological  weapons
and are  included  on  the  CDC’s  list  of  possible  bioter-
rorism  threat  agents  [4].  Brucellosis  is  endemic  in
Georgia and  causes  approximately  150  registered
cases annually  [5].
The  gold  standard  for  the  diagnosis  of  brucellosis
is culture  isolation  [6].  This  method  is  relatively
insensitive because  Brucellae  are  fastidious  organ-
isms; in  addition,  many  patients  receive  antibiotics
before  hospital  admission,  which  reduces  the
chance  of  obtaining  a  positive  culture.  Direct
detection of  the  organism  by  PCR  from  clinical
samples has  been  used  with  varying  degrees  of
success [6].  Thus,  the  diagnosis  of  brucellosis
often relies  on  the  detection  of  immunological
evidence  of  exposure  to  speciﬁc  antigens  using
antibody-based  blood  tests.  A  variety  of  com-
mercial kits  and  protocols  exist  that  are  able  to
measure Brucella-speciﬁc  antibodies.  In  Georgia,
the diagnosis  of  brucellosis  is  predominantly  based
on clinical  suspicion  and  slide  (Huddelson)  and
tube (Wright)  agglutination  tests,  which  measure
antibodies  speciﬁc  to  Brucella.  Tests  that  measure
other  aspects  of  the  immune  response  to  Brucella
are not  routinely  used  for  diagnosis.  However,  tests
based on  cell-mediated  immune  (CMI)  responses
have been  used  in  the  past.  For  example,  a
i
r
belayed-type  hypersensitivity  reaction,  the  Burne
kin test,  was  developed  and  used  for  diagnosis  of
uman brucellosis  in  Georgia  until  the  early  1980s.
his test  was  ultimately  abandoned  because  of  the
igh frequency  of  hypersensitivity  reactions.  The
iagnosis of  Brucella  using  speciﬁc  skin  tests  has
lso been  considered  as  an  option  elsewhere  in  the
orld [7].  Overall,  the  human  immune  response
o infection  with  Brucella  species,  particularly  the
MI response,  is  incompletely  understood  [8].  A
umber of  studies  have  been  conducted  on  acutely
nd chronically  infected  patients  that  indicate  that
he immune  response  to  Brucella  has  many  facets
9—11].  However,  much  remains  to  be  elucidated
efore the  intricacies  of  the  human  immune
esponse to  Brucella  can  be  fully  understood.
A better  understanding  of  the  immune  response
o this  organism  could  aid  in  the  development  of
ew diagnostic  and  prognostic  methods  and  could
ontribute  to  the  development  of  medical  counter-
easures,  including  immunomodulatory  therapies
r vaccines.  Because  Brucella  is an  intracellular
athogen, it  is  likely  that  a  strong  CMI  response
s needed  for  protection  against  Brucella  infec-
ion. Indeed,  this  requirement  has  been  veriﬁed
n research  with  mice  that  are  deﬁcient  for  CD8+
-cells  [12].
For  the  reasons  outlined  above,  it  is  crucial
o identify  patient  populations  with  brucellosis
nd undertake  studies  to  further  characterize  the
mmune response.  In  the  present  study,  we  enrolled
3 patients  that  had  been  previously  diagnosed
ith brucellosis  and  investigated  their  immune
esponses using  the  ELISPOT  and  ELISA  to  assess
ong-term  CMI  and  antibody  responses  to  Brucella
ntigens. We  also  collected  epidemiological  and
linical information  and  laboratory  results.  The
verall aim  of  the  investigation  was  to  establishng clinical  procedures  and  diagnostic  assays  and  to
evisit the  feasibility  of  conducting  CMI  response-
ased diagnosis  using  new  ex  vivo  analogs  of  the
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elayed-type  hypersensitivity  reaction  test  (Burne
est).
ethods
atients
olunteers  were  recruited,  after  informed  con-
ent had  been  obtained,  from  patients  who
ad been  treated  at  the  S.  Virsaladze  Scientiﬁc
esearch Institute  of  Medical  Parasitology  and  Trop-
cal Medicine  (Institute  of  Parasitology),  Tbilisi,
eorgia.  This  hospital  has  maintained  discharge
iagnosis records  for  many  years,  and  the  hospi-
al personnel  are  able  to  identify  patients  with
 discharge  diagnosis  of  brucellosis.  The  study
nvolved a  single  blood  draw  from  adult  volun-
eers (aged  >18  years)  who  had  been  diagnosed
ith brucellosis  between  3  and  12  months  prior
o enrollment  in  the  study.  The  volunteers  were
sked  to  assist  in  completing  a  Brucellosis  Clinical
ssessment  Questionnaire  regarding  their  clini-
al signs  and  symptoms  of  infection,  exposure
istory, and  treatment  before  and  during  hospi-
alization. The  patients  had  received  a  variety  of
ntibiotic  regimens,  including  streptomycin,  tetra-
ycline, chloramphenicol,  rifampin,  gentamicin  or
oxycycline.  Additionally,  patient  charts  and  outpa-
ient logs  were  reviewed  to  obtain  the  clinical  and
aboratory  data.
aboratory tests at initial diagnosis
wo  serological  tests,  Huddelson’s  and  Wright’s
ests [1],  which  measure  a  speciﬁc  antibody  to  Bru-
ella, were  used  to  make  a  presumptive  diagnosis
f brucellosis.  Both  tests  are  antibody  agglutination
ests. The  Huddelson’s  slide  agglutination  test  pro-
ides a  qualitative  visual  record  of  agglutination,
nd the  Wright’s  test  (tube  serum  agglutination
est, SAT)  allows  for  the  measurement  of  the  anti-
ody titer.  A  titer  of  1/200  or  higher  was  considered
o be  positive.
The full  blood  count  and  the  erythrocyte  sed-
mentation rate  (ESR)  data  were  available  for  19
atients at  initial  diagnosis  (Fig.  1).  The  hemoglobin
oncentration,  total  red  and  white  cell  counts,  lym-
hocyte count  and  ESR  values  that  were  measured
t admission  were  collected  and  recorded  in  the
atients’  study  ﬁles  upon  enrollment.
ample collection during enrollment into
he study
lood  was  obtained  from  all  43  patients  that  were
nrolled  in  the  study  and  tested  for  the  presence
t
d
t
a323
f Brucella-speciﬁc  cellular  and  humoral  immune
esponses.  Venous  blood  was  collected  at  the
olunteer’s home  into  sodium  citrate-containing
acutainer  cell  preparation  tubes  (CPTs)  and  serum
ubes (Becton  DickinsonTM). The  blood  samples
ere transported  to  a  laboratory  at  the  National
enter for  Disease  Control  and  Public  Health
NCDC), Tbilisi,  and  processed  within  4  h of  collec-
ion.
LISA
he  serum  for  the  ELISA  was  obtained  by  centrifug-
ng the  clotted  blood  at  1200  × g for  15  min
t room  temperature.  The  serum  was  aspirated
nto clean  tubes  and  maintained  at  −80 ◦C  until
equired.
The antibody  responses  to  Brucella  LPS  were
easured using  a  competitive  ELISA  (COMPELISATM
it).  The  test  was  provided  by  the  Veteri-
ary Laboratories  Agency  (VLA),  UK,  and  was
erformed  according  to  the  manufacturer’s  instruc-
ions. Brieﬂy,  20  l  of  the  test  or  control  sera
ere placed  into  each  well  of  a  96-well  plate
nd diluted  to  1:6,  after  which  freshly  prepared
onjugate solution  was  immediately  added.  The
late was  mixed  vigorously  for  2  min  and  incu-
ated for  30  min  with  constant  shaking  at  room
emperature.  After  extensive  washing,  each  plate
as developed  using  SigmaFastTM OPD  tablets
Sigma—Aldrich),  and  the  optical  density  (OD)  was
easured  (450  nm).  The  cut-off  value  was  calcu-
ated as  60%  of  the  mean  OD  of  four  conjugate
ontrol wells.  Any  test  sample  with  an  OD  equal
o or  below  this  value  was  considered  to  be
ositive.
Speciﬁc antibody  responses  to  Brucella-speciﬁc
roteins (using  BrucellergeneTM OCB  as  an  antigen,
ynbiotics  Corp.,  Merial,  France)  were  measured
sing an  indirect  ELISA  developed  in-house  at  the
CDC. Brieﬂy,  96-well  plates  were  coated  overnight
ith brucellergene  at  a ﬁnal  concentration  of
 g/ml  in  PBS  and  blocked  with  5%  milk  in  1×  PBS
ontaining 0.1%  Tween-20  (PBST).  Serial  dilutions
1:50—1:102  400)  of  each  test  sample  were  placed
nto the  preliminary  washed  wells  of  a microtiter
late and  incubated  for  1  h  at  37 ◦C.  The  wells  were
ashed  ﬁve  times  with  PBST  and  incubated  for  1  h
t 37 ◦C  with  an  afﬁnity-puriﬁed  peroxidase-labeled
oat anti-human  antibody  IgG  (KPL)  at  a  ﬁnal  dilu-
ion of  1:1000  in  5%  milk/PBST.  The  wells  were
eveloped  using  the  ABTS  peroxidase  substrate  sys-
em and  stop  solution  (KPL).  Readings  were  taken
t 405  nm.
324  T.  Akhvlediani  et  al.
Figure  1  Interactions  between  the  parameters  that  were  measured  in  patients  that  were  diagnosed  with  Brucella
3—12  months  before  recruitment  to  this  study.  Panel  A  shows  that  individuals  who  reported  that  they  had  complications
with  their  disease  presented  to  a  medical  professional  earlier  (shown  with  a  box-and-whisker  plot  and  the  result  from
a  T-test).  Panel  B  shows  that  older  individuals  were  more  likely  to  suffer  concomitant  disease  (shown  with  a box-and-
whisker  plot  in  which  different  diseases  have  been  pooled  with  the  results  of  the  ANOVA).  Panel  C  shows  the  correlation
between  the  SAT  tests  used  to  diagnose  Brucella  (shown  as  a  dot  plot  with  the  results  from  Spearman’s  correlation).
Panel  D  shows  a  negative  correlation  between  the  patients’  hemoglobin  and  lymphocyte  concentrations  at  the  time  of
diagnosis  (shown  as  a  scatter  plot  with  the  results  from  Pearson’s  correlation).  Panel  E  shows  that  the  ESR  taken  at  the
time  of  diagnosis  was  more  likely  to  be  higher  in  individuals  who  suffered  symptoms  after  the  completion  of  antibiotic
therapy  (shown  as  a  box-and-whisker  plot  with  the  results  from  a  T-test.  The  antibiotic  therapy  included  a  variety  of
regimens  prescribed  by  medical  staff  including  streptomycin,  tetracycline,  chloramphenicol,  rifampin,  gentamicin  or
doxycycline).  Panel  F  shows  that  the  ERS  taken  at  the  time  of  diagnosis  was  likely  to  be  higher  in  patients  that  were
hospitalized  (shown  as  a  box-and-whisker  plot  with  the  results  from  a  T-test).  Panel  G  shows  a  negative  correlation
between  the  patients’  antibody  titers  to  Brucella  LPS  and  to  BrucellergeneTM at  the  time  of  enrollment  (shown  as  a
scatter  plot  with  the  results  from  Pearson’s  correlation).  Panel  H  shows  that  the  patients’  antibody  titers  to  Brucella
LPS  at  the  time  of  enrollment  was  likely  to  be  higher  in  outpatients  (shown  as  a  box-and-whisker  plot  with  the  results
from  a  T-test).  Panel  I  shows  that  the  patient’s  antibody  titer  to  Brucella  LPS  at  the  time  of  enrollment  was  likely
to  be  higher  in  patients  who  had  no  prior  exposure  to  animals  (shown  as  a  box-and-whisker  plot  with  the  results
from  a  T-test).  Panel  J  shows  that  the  patient’s  antibody  titer  to  BrucellergeneTM at  the  time  of  enrollment  was
likely  to  be  higher  in  patients  that  had  complications  (shown  as  a box-and-whisker  plot  with  the  results  from  a  T-
test).  Panel  K  shows  a  negative  correlation  between  the  patients’  antibody  titers  to  BrucellergeneTM at  the  time  of
enrollment  and  the  lymphocyte  concentration  at  time  of  diagnosis  (shown  as  a  scatter  plot  with  the  results  from  the
Pearson’s  correlation).  Panel  L  shows  a  correlation  between  patients’  antibody  titers  to  BrucellergeneTM at  the  time
of  enrollment  and  hemoglobin  concentration  at  the  time  of  diagnosis  (shown  as  a  scatter  plot  with  the  results  of  the
Pearson’s  correlation).  Panel  M  shows  a  negative  correlation  between  the  patients’  antibody  titers  to  BrucellergeneTM
and  IFN- ELISPOT  responses  to  BrucellergeneTM at  the  time  of  enrollment  (shown  as  a  scatter  plot  with  the  results
from  the  Pearson’s  correlation).
M s  
E
P
p
m
s
p
i
B
t
a

S
s
P
a
t
a
t
w
b
I
a
b
w
o
t
t
w
C
a
s
E
E
n
S
c
n
(
t
A
f
e
i
t

f
o
c
a
S
T
a
p
‘
F
t
d
s
p
v
t
u
c
p
b
F
w
m
w
r
R
D
A
f
d
c
n
p
a
b
o
w
p
u
2
n
i
a
a
a
t
o
p
i
d
4
4
aemory  immune  response  to  Brucella  sp.  in  human
LISPOT assays
eripheral  blood  mononuclear  cells  (PBMCs)  were
repared  and  washed  in  RPMI  medium  supple-
ented with  10%  fetal  calf  serum,  penicillin,
treptomycin,  and  L-glutamine.  ELISPOTs  were
erformed as  described  in  the  manufacturer’s
nstructions  (BDTM ELISPOT,  Becton  Dickinson).
rieﬂy, 0.5  ×  106 cells  were  added  to  each  well  of
he ELISPOT  plates,  which  were  pre-coated  with
ntibodies  to  interleukin-5  (IL-5)  and  interferon-
 (IFN-).  Brucellergene  (BrucellergeneTM OCB,
ynbiotics Corp.,  Merial,  France)  was  used  as  a
timulating  speciﬁc  antigen  after  dialysis  against
BS to  remove  preservative.  The  antigen  was
dded at  12.5  g/ml  (ﬁnal  concentration),  and
he plates  were  incubated  overnight  at  37 ◦C  in
 5%  CO2,  humidiﬁed  atmosphere.  Subsequently,
he cells  were  washed  away,  and  the  plates
ere developed  by  the  addition  of  an  appropriate
iotinylated cytokine-detection  antibody  (to  either
L-5 or  IFN-),  which  was  followed  by  incubation
t room  temperature  for  2  h.  Any  unbound  anti-
odies  were  removed  by  washing  three  times  with
ash buffer,  and  then  streptavidin  horseradish  per-
xidase conjugate  was  added.  After  incubation,
he enzyme  conjugate  was  removed  by  washing
hree times,  and  the  ﬁnal  development  of  the  spots
as performed  with  3-amino-9-ethylcarbazole  (AEC
hromogen  kit,  Sigma).  The  spots  were  enumer-
ted (intensity  3,  size  8,  gradient  1  and  well
aturation 83%)  using  an  ELISPOT  Reader  system
LR04  (Advanced  Imaging  Devices,  GmbH)  and  the
LISPOT Reader  4.0  software  (Autoimmune  Diag-
ostika,  GmbH).  Concanavalin  A  (ConA)  (2  g/ml,
igma Aldrich)  was  used  as  a  positive  control;  when
ells failed  to  react  to  ConA,  the  samples  were
ot considered  for  further  analysis.  Unstimulated
blank) controls  were  also  included  for  each  sample
hat consisted  of  cells  cultured  in  medium  alone.
ll of  the  conditions  were  assayed  in  triplicate
or each  blood  sample.  The  results  were  consid-
red to  be  positive  when  greater  than  a  threefold
nduction of  cytokine  excretion  was  observed  over
he background.  As  additional  controls,  the  IFN-
 and  IL-5  responses  were  measured  in  samples
rom seven  individuals  (aged  28—60;  six  males,
ne female)  with  no  known  prior  exposure  to  Bru-
ella and  who  were  not  taking  any  drugs,  including
ntibiotics.
tatistical analysishe  data  were  analyzed  using  MINITAB  V14.0.  For
nalysis,  data  were  generated  for  the  following
arameters: ‘‘Time  from  symptoms  to  hospital’’,
o
p
(
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‘Brucellergene  OCB  ELISA’’,  and  ‘‘CompELISATM’’.
urthermore,  all  of  the  ELISPOT  data  were  log10
ransformed  to  ensure  a better  ﬁt  to  a normal
istribution as  is  required  for  parametric  analy-
is. Comparisons  of  two  continuous  variables  were
erformed  using  two  sample  T-tests  where  equal
ariances  were  not  assumed.  Comparisons  of  more
han two  continuous  variables  were  performed
sing a 1-way  ANOVA.  Explorations  of  the  asso-
iations between  two  continuous  variables  were
erformed  using  Pearson’s  correlations.  The  num-
er of  ELISPOT  responders  was  compared  using
isher’s  exact  test.  The  initial  diagnostic  tests
ere correlated  using  Spearman’s  nonparametric
ethod. The  blood  test  data  collected  at  admission
ere  compared  to  standard  laboratory  reference
anges [13,14].
esults
emographics and clinical characteristics
 total  of  43  adult  patients  (39  males  and  four
emales) were  enrolled  in  the  study.  The  initial
iagnosis of  brucellosis  was  established  based  on
linical suspicion  and  positive  slide  or  tube  aggluti-
ation  tests.  Nine  patients  were  hospitalized  after
resentation;  the  remaining  34  cases  were  man-
ged as  outpatients.
Occupational  exposure  to  animals  was  reported
y 63%  of  the  patients.  Most  subjects  (84%
f the  total  cohort)  had  a history  of  contact
ith animals  before  diagnosis,  and  37%  of  the
atients  had  consumed  unpasteurized  dairy  prod-
cts and  undercooked  meat  in  the  preceding
 months.  The  data  obtained  from  the  question-
aire responses  suggested  that  the  majority  of
nfections  were  acquired  after  direct  contact  with
nimals, with  28  (65%)  of  the  43  patients  reporting
griculture-related  occupations  (shepherd,  farmer
nd butcher)  and  16  (37%)  reporting  the  consump-
ion of  unpasteurized  dairy  products  before  the
nset of  symptoms.  The  symptoms  included  back
ain (2  of  26,  7.7%),  fever  (41  of  43,  95.3%),  sweat-
ng (33  of  43,  76.7%),  malaise  (3  of  43,  7.0%),
epression (2  of  43,  4.6),  general  weakness  (4  of
3, 9.3%),  arthralgia  (37  of  43,  86.0%),  myalgia  (1  of
3, 2.3%),  sacroiliitis  (2  of  43,  4.6%)  and  peripheral
rthritis  (1  of  43,  2.3%).
Seven  patients  had  complications  at  the  timef brucellosis  diagnosis,  including  sacroiliitis  (2),
eripheral arthritis  (2)  and  epididymo-orchitis
3). Individuals  with  complications  were  found
o present  to  the  hospital  within  a shorter  time
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period  after  the  onset  of  symptoms.  Thus,  for  the
seven patients  with  complications,  the  geometric
mean time  between  the  development  of  symptoms
and presentation  was  12  days,  whereas  for  the  36
patients without  complications,  the  mean  interval
was 27  days  (p  =  0.005,  T  test  for  the  7  patients  with
complications  [mean  =  1.107  log10 days  from  onset
of symptoms  to  presentation  ±  0.077  SEM]  and  for
the 36  without  complications  [mean  =  1.447  log10
days  ±  0.075  SEM],  Fig.  1A).
The  mean  interval  between  time  of  brucel-
losis diagnosis  and  enrollment  into  the  study
was 7 months.  Twenty-six  subjects  (61%)  were
still symptomatic  at  enrollment.  Additionally,
documented  relapse  of  symptoms  after  treat-
ment (i.e.,  clinical  relapse)  was  recorded  in
six patients  (14%).  There  was  no  correlation
between  the  presence  of  symptoms  and  the
interval between  diagnosis  and  enrollment  or
the age  of  the  patients  (p  >  0.05).  Thirty-one
patients did  not  have  concomitant  disease  (mean
age =  38.78  years).  The  other  12  patients  had  con-
comitant  diseases;  diabetes  mellitus  (n  =  3,  mean
age =  48.26  years)  and  hypertension  (n  =  6,  mean
age =  60.28  years)  were  more  common  in  older
people (p  =  0.046,  1-way  ANOVA,  Fig.  1B).  Addi-
tionally,  two  patients  had  hepatitis  C  (one  of
them complicated  by  liver  cirrhosis)  and  one  had
gout.
Laboratory results at the time of primary
diagnosis
Slide  and  Wright  SAT  test  results  were  available
for 39  cases.  There  was  a  high  degree  of  concord-
ance between  test  results  (p  <  0.01,  Spearman’s
correlation, Fig.  1C).  Limited  analysis  had  been
performed  on  the  blood  from  the  19  patients
(Fig. 1).  The  hemoglobin  concentrations  (n  =  19,
mean = 126.1  g/L  ±  1.83  SEM)  were  negatively  cor-
related with  the  lymphocyte  counts  (n  =  19,
mean = 2.546  ×  103 cells/l  ±  0.1941  SEM)  at  pre-
sentation (p  =  0.035,  Pearson’s  r  =  −0.485,  Fig.  1D).
The ESR  was  signiﬁcantly  higher  (p  <  0.048,  T-test,
Fig. 1E)  in  patients  who  remained  symptomatic
after treatment  (n  =  11,  mean  ESR  =  22.9  ±  4.0  SEM)
compared  with  individuals  that  were  asymptomatic
after treatment  (n  =  8,  mean  ESR  =  12.7  ±  2.5  SEM).
The ESR  was  signiﬁcantly  higher  in  patients  who
were admitted  to  the  hospital  at  presentation
(n =  9,  mean  ESR  =  25.2  ±  4.5  SEM)  than  in  those
who were  not  (n  =  10,  mean  ESR  =  12.7  ±  2.0  SEM)
(p = 0.030,  T-test,  Fig.  1F).
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aboratory results at the time of the
nrollment into the study
n  exhaustive  series  of  statistical  comparisons  was
ade between  all  of  the  data  sets  (initial  diagnostic
arameters,  questionnaire  data,  and  enrollment-
oint laboratory  tests).  The  signiﬁcant  interactions
bserved in  this  exhaustive  analysis  are  summarized
n Fig.  2.  We  report  all  observed  positive  results
ut only  the  negative  results  that  we  believe  to  be
mportant.
Sera from  all  43  patients  were  assessed  by  ELISA.
n total,  35  of  42  (83%)  patients  were  positive  for
ntibodies  to  Brucella  LPS  by  COMPELISA,  and  34  of
8 patients  (89%)  had  demonstrable  speciﬁc  anti-
odies to  Brucellergene  OCB  antigens  (Fig.  1G).
here was  a  correlation  between  the  results
btained from  the  two  ELISAs  (p  =  0.031,  Pear-
on’s r  =  0.851).  Furthermore,  there  was  evidence
or weaker  LPS  antibody  responses  (by  COMPELISA)
n outpatients  (p  =  0.023,  T-test)  and  in  patients
eporting exposure  to  livestock  (p =  0.002,  T-test).
here was  no  association  between  BrucellergeneTM
LISA  results  and  reported  exposure  to  ani-
als or  in-patient/out-patient  status  (p  >  0.05).
owever,  patients  presenting  with  complications
ad higher  antibody  responses  to  BrucellergeneTM
han  those  without  complications  (p  =  0.005,  T
est). There  was  a  weak  negative  correla-
ion between  BrucellergeneTM-speciﬁc  antibody
esponses and  lymphocyte  concentrations  at  enroll-
ent (p  =  0.050,  Pearson’s  r  =  −0.469).  Further-
ore, a  signiﬁcant  positive  correlation  between
rucellergeneTM-speciﬁc  antibody  responses  and
emoglobin  concentration  was  observed  (p =  0.043,
earson’s  r  =  0.483)  (Fig.  1K  and  L).  However,
o signiﬁcant  correlations  between  hemoglobin,
ymphocyte concentrations  and  COMPELISA  results
p > 0.05)  were  demonstrated.
Blood samples  from  15  patients  (35%)  were
ssessed for  CMI  responses  to  brucellergene  OCB.
ll 15  patients  were  positive  for  antigen-speciﬁc
licitation  of  IFN-  (100%).  Only  14  valid  patient
LISPOTS were  obtained  for  IL-5,  of  which  8  (57%)
ere considered  to  be  positive.  None  of  the  seven
ontrol  subjects  (those  with  no  history  of  Bru-
ella)  elicited  measurable  cytokine  responses  to
rucella-speciﬁc  antigens.  There  were  signiﬁcant
ifferences between  the  antigen-speciﬁc  cytokine
esponses  for  patients  and  unexposed  controls
IL-5, p  =  0.018;  IFN-,  p <  0.001,  Fisher’s  exact
est.) There  was  a  signiﬁcant  inverse  correlation
etween brucellergene-speciﬁc  antibody  and  IFN-
LISPOT responses  (p  =  0.017,  Pearson’s  r  =  −0.762)
Fig. 1)  but  no  correlation  with  IL-5  ELISPOT
esponses (p  > 0.05).  Neither  cytokine  response
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Figure  2  A  diagrammatic  representation  of  the  signiﬁcant  interactions  between  the  characteristics  of  Brucella
patients  in  Georgia.  These  characteristics  have  been  subdivided  into  the  following  categories:  questionnaire  data
(whether  the  disease  was  complicated,  the  period  of  time  elapsed  from  onset  of  symptoms  to  presentation  to  health
professionals,  whether  patients  had  exposure  to  livestock  before  infection,  patient  age  at  the  time  of  diagnosis,  pres-
ence  of  concomitant  disease,  whether  the  patient  was  treated  as  an  outpatient  and  whether  they  suffered  disease
symptoms  post  treatment),  the  results  of  clinical  tests  administered  at  the  time  of  diagnosis  (Slide  or  Wright  SAT,
ESR,  hemoglobin  and  lymphocyte  counts)  and  speciﬁc  immunological  measurements  obtained  3—12  month  post  diag-
nosis  (antibody  ELISA  to  BrucellergeneTM or  LPS  and  IFN- ELISPOT  responses  to  BrucellergeneTM).  The  interactions
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retween  these  parameters  are  shown  as  double-ended  a
ouble-ended  lines.  The  full  details  of  these  interactions
as  correlated  with  the  COMPELISA  responses
p >  0.05).
There  were  no  correlations  between  any  aspects
f humoral  or  CMI  response  and  the  time  between
he onset  of  symptoms  and  enrollment  (p  >  0.05
n all  cases).  Furthermore,  we  observed  no  differ-
nces  in  antibody  or  CMI  response  when  comparing
hose that  were  symptomatic  at  the  time  of  enroll-
ent  and  those  who  were  not  (p  >  0.05  in  all  cases).
iscussion
n  this  study,  we  explored  long-term  immunity  in  a
ohort of  individuals  that  had  been  previously  diag-
osed with  brucellosis,  many  of  whom  were  still
ymptomatic.  Although  conﬁrmation  of  the  diag-
osis by  positive  culture  was  not  available  for  any
f the  subjects,  our  data  support  the  diagnosis  of
rucellosis  in  the  majority  of  cases.
The patients  reported  a  variety  of  symptoms,
nd there  was  no  evidence  of  a  correlation  between
ifferent symptoms  and  the  clinical  and  diagnos-
ic parameters  that  were  measured.  These  ﬁndings
e
b
c
cs,  and  negative  interactions  are  represented  by  broken
 the  statistical  analysis  are  shown  in  Fig.  1.
re  consistent  with  published  data  on  brucellosis
s a complex  disease  with  a  multifaceted  clinical
resentation  [3,15].  Additionally,  we  found  sev-
ral results  that  could  easily  be  explained.  Patients
ith  complications  were  found  to  present  to  the
ospital  within  a shorter  time  period  after  the
nset of  symptoms;  such  individuals  may  already
ave been  in  contact  with  medical  professionals
r had  more  severe  disease.  Individuals  with  con-
omitant  disease  were  more  likely  to  be  older;  the
isease burden  was  greater  with  age.  ESR  values
ere greater  in  individuals  who  were  symptomatic
fter treatment  and  in  in-patients,  which  are  both
actors that  may  indicate  more  severe  disease.  In
revious studies,  ESR  has  been  shown  to  be  linked
ith cytokine  production  [16];  however,  in  the  pre-
ious work,  the  cytokine  levels  were  measured
uring the  progression  of the  disease,  whereas  our
easurements  were  taken  post-infection.  For  these
easons, we  believe  that  these  data  sets  support
ach other.  Other  results,  such  as  the  relationship
etween lymphocyte  concentration,  hemoglobin
oncentration  and  the  humoral  response  to  bru-
ellergene,  have  no  obvious  explanation.  Analysis
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of  questionnaire  and  clinical  data  generated  at
the time  of  initial  presentation  increases  our  con-
ﬁdence  that  individuals  had  been  infected  by
Brucella,  and  the  symptoms  in  Georgia  are  congru-
ent with  our  current  understanding  of  the  disease
[2]. Unfortunately,  it  was  not  possible  to  accu-
rately  determine  the  period  of  time  that  elapsed
between initial  diagnosis  and  relapse  in  this  study.
Previous  data  have  shown  that  weak  immune
responses to  Brucella  can  affect  the  likelihood  of
relapse [17].
At  enrollment  into  the  study,  a large  propor-
tion (>80%)  of  patients  were  serologically  positive
for Brucella  LPS  and  protein  (BrucellergeneTM),
and Brucella  protein  was  detected  by  the  CMI
assay. This  observation  provides  us  with  further
conﬁdence  that  our  cohort  of  patients  was  orig-
inally  infected  with  Brucella.  Positivity  in  the
CompELISA  assay  was  determined  as  an  OD  value
of greater  than  60%  of  the  positive  control  sera,
according  to  the  manufacturer’s  recommendations.
However, this  assay  has  not  been  validated  for  the
diagnosis of  human  brucellosis,  and  a  full  assess-
ment  of  the  utility  of  the  CompELISA  for  use  in
human  diagnosis  was  not  within  the  scope  of  this
study. Nevertheless,  the  existence  of  strong  Com-
pELISA (LPS-speciﬁc  antibody)  and  BrucellergeneTM
(cytosolic  antigen-speciﬁc  antibody)  responses  sug-
gests that  a  sustained  and  robust  memory  response
and/or  continued  exposure  to  antigen  exist.  Fur-
thermore,  we  observed  a  good  correlation  between
the results  of  the  ELISA  for  antibody  response
to LPS  and  to  BrucellergeneTM;  the  majority  of
patients  mounted  speciﬁc  antibody  responses  to
both antigens.  This  observation  indicates  that  after
presentation  and  treatment,  the  humoral  immune
system  is  capable  of  recognizing  a  variety  of  Bru-
cella antigens.  Furthermore,  it  indicates  that  the
humoral immune  response  to  Brucella  antigens
is long-lived,  as  these  responses  were  detected
up to  12  months  after  initial  diagnosis  and  treat-
ment of  brucellosis.  The  longevity  of  anti-Brucella
responses  is  well  documented,  and  persistent  SAT
titers of  greater  than  1:320  have  been  recorded
in patients  with  resolved  infection  [18].  Previous
studies have  investigated  the  diagnostic/prognostic
potential  of  different  antibody-based  techniques
for human  brucellosis.  Baldi  et  al.  [19]  observed
that ELISA  results  correlated  well  with  clinical  out-
comes (resolution,  persistence  and  relapse  of  signs
and symptoms).  In  contrast  to  the  study  described
by Baldi  et  al.,  we  did  not  observe  a  signiﬁcant
positive correlation  between  the  immune  response
and the  relapse  of  symptoms,  although  this  lack  is
likely a  reﬂection  of  the  low  power  of  our  study.
In addition,  this  study  concluded  that,  although
r
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PS  would  be  an  excellent  candidate  for  diagnos-
ics, due  to  the  cross-reactivity  of  the  LPS  protein,
PS-depleted  cytosolic  extract  might  be  a prefer-
ble method.  With  these  observations  in  mind,
t appears  to  be  more  likely  that  many  of  our
atients had  not  cleared  the  infection  completely.
antecon et  al.  [20]  explored  antibody  subtypes
n detail  and  found  similar  results.  Memish  et  al.
21] found  that  both  IgG  and  IgM  should  be  mea-
ured  to  assure  good  speciﬁcity  and  sensitivity.  Our
imple ELISAs  for  LPS  and  protein  are  not  isotype-
peciﬁc.
In our  studies,  an  association  between  an
ntibody response  to  Brucella  LPS  (but  not
rucellergeneTM) and  outpatient  status  (out-
atients have  a greater  response)  and  patients
eporting contact  with  livestock  was  observed
those with  contact  had  a  greater  response).
e also  observed  an  association  between  the
rucellergeneTM-speciﬁc  responses  and  patients
eporting complications  (in  which  those  with  com-
lications  had  a  greater  antibody  response).  The
eaker antibody  responses  to  Brucella  LPS  in
atients  that  reported  contact  with  livestock  are
ifﬁcult to  explain;  however,  this  ﬁnding  might  be
ue to  an  immune  tolerance  to  a previously  rec-
gnized  antigen.  Stronger  brucellergene-speciﬁc
ntibody  responses  in  patients  that  reported  com-
lications  may  reﬂect  a  more  protracted  course
f disease  and  longer-term  exposure  to  Bru-
ella, which  allowed  for  recognition  of  a more
iverse range  of  antigens.  Interrogation  of  the  ini-
ial clinical  laboratory  tests  and  humoral  immune
esponses  upon  enrollment  in  the  study  revealed  a
eak inverse  correlation  between  total  lymphocyte
ounts and  antibody  responses  to  BrucellergeneTM.
his association  could  reﬂect  the  maturity  of  the
mmune  response  and  be  related  to  the  chang-
ng nature  of  antigen  recognition  as  infection
rogresses from  initial  antigen  encounter  to  a
ore chronic  disease.  Overall,  these  observations
egarding humoral  immunity  suggest  that  a  bru-
ellergene/LPS  differential  diagnostic  for  human
rucellosis  could  potentially  be  used  in  future  stud-
es to  improve  the  understanding  of  human  disease
rogression.
Measurements  of  CMI  responses,  such  as  intra-
ermal  delayed-type  hypersensitivity  reactions
allergic skin  test),  have  been  investigated  for
se as  diagnostic  methods  for  animal  brucellosis
22,23], and  analogous  assays  have  been  developed
hat  measure  the  ex  vivo  elicitation  of  IFN-  in
esponse  to  stimulation  with  skin  test  antigens  [24].
or this  study,  ELISPOT  assays  that  measure  the
roduction  of  IFN-  and  IL-5  by  ex  vivo  stimulated
BMCs were  used  to  investigate  the  CMI  responses
M s  
o
b
5
u
n
I
t
r
a
t
t
f
m
s
b
p
5
e
i
c
t
b
b
w
s
t
s
s
a
c
t
n
T
s
p
a
d
t
B
(
p
B
b
d
b
i
i
m
e
g
s
c
r
w
r
t
t
o
t
d
L
r
s
s
g
t
t
w
c
G
e
c
o
a
a
a
o
o
o
a
l
p
a
ﬁ
e
n
p
r
t
p
a
r
n
t
l
i
p
a
i
l
d
v
t
t
a
i
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f  patients.  All  of  the  patients  tested  were  capa-
le of  eliciting  an  IFN-  response  (Th1),  but  only
7% produced  a  measurable  IL-5  response  (Th2)
pon  recall  stimulation.  Control  subjects  revealed
o increase  in  the  production  of  either  IFN-  or
L-5 in  response  to  speciﬁc  Brucella  antigen  stimula-
ion,  which  suggests  that  the  assays  were  measuring
esponses that  are  speciﬁc  to  brucellosis  infection
nd could  provide  a  basis  for  a  valuable  diagnos-
ic approach.  However,  it  should  be  noted  that
he sample  size  in  these  studies  was  small  and
urther  investigations  would  be  necessary  to  deter-
ine the  diagnostic  and  analytical  sensitivity  and
peciﬁcity  of  these  approaches  before  they  could
e used  for  clinical  diagnosis  of  brucellosis.  The
roduction  of  IFN-  from  all  (100%)  patients  and  IL-
 from  only  57%  of  patients  is  consistent  with  the
xpected  Th1  bias  that  is  associated  with  Brucella
nfection  [25].  In  addition,  we  observed  an  inverse
orrelation  between  IFN-  production  in  response
o brucellergene  stimulation  and  demonstration  of
rucellergene-speciﬁc  antibodies.  This  effect  may
e related  to  Th1/2  switching  in  these  patients,
hich suggests  that  the  antibody  responses  are
trongest  where  the  cellular  responses  are  rela-
ively  weak.  These  data  may  relate  to  different
tages of  immune  development  or  disease  progres-
ion and  resolution  in  these  patients.  A  shift  from
 dominant  Th1—Th2  response  has  previously  been
orrelated  with  the  development  of  chronic  infec-
ion [26].  Furthermore,  targeted  investigations  are
ecessary to  fully  elucidate  these  ﬁndings  where
h1/2  biasing  would  be  measured  during  the  acute
tage of  the  disease.
These  data  also  raise  the  possibility  that  com-
onents  of  Brucellergene  (or  alternative  Brucella
ntigens)  may  warrant  further  investigation  as
iagnostic  antigens  for  human  brucellosis  and,  par-
icularly, as  stimulating  antigens  for  CMI  assays.
rucellergene  contains  two  known  immunogens
Brucella bacterioferritin  and  P39,  a  putative
eriplasmic substrate-binding  protein  [27])  [28].
rucellergene  (sometimes  termed  brucellin)  has
een considered  favorably  for  the  development  of
iagnostics  in  the  past.  Cellular  responses  have
een investigated  in  conﬁrmatory  diagnostic  test-
ng in  the  ﬁeld  of  animal  health  and  disease  control
n which  Brucellergene  was  used  in  an  intrader-
al delayed-hypersensitivity  test  to  indicate  prior
xposure  and  adaptive  immunity  to  cytosolic  anti-
ens of  Brucella  [29,30].  In  vitro  tests  to  measure
peciﬁc IFN-  from  the  supernatants  of  stimulated
ells were  also  assessed  for  this  purpose.  The
ationale for  the  assessment  of  cellular  responses
as to  compare  cellular  responses  to  antibody
esponses to  Brucella  proteins  or  to  Brucella  LPS,
a
M
t
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hus  possibly  providing  a more  conﬁdent  predic-
ion of  active  infection.  However,  varying  degrees
f success  were  observed  with  this  approach.  The
raditional  serodiagnosis  of  Brucella  relies  on  the
etection  of  antibodies  to  the  immuno-dominant
PS. Assessment  of  the  cellular  and  serological
esponse to  proteins  would  offer  an  alternative
peciﬁcity of  antigens  for  diagnosis.  This  study
ought  to  investigate  the  utility  of  protein  anti-
ens for  this  purpose.  Weynants  et  al.  [23]  found
he test  to  be  useful  as  a  conﬁrmatory  diagnos-
ic test  when  a  false  positive  serological  reaction
as observed,  whereas  Kittelberger  et  al.  [22]  con-
luded that  the  test  had  sub-optimal  speciﬁcity.
iambartolomei  et  al.  [11]  found  that  IFN- lev-
ls were  dependent  on  whether  the  disease  was
hronic or  acute  and  that  these  responses  decayed
ver a period  of  greater  than  a  year.  In  our  study,
ll of  the  patients  were  enrolled  less  than  a  year
fter the  initial  diagnosis;  therefore,  we  were  not
ble to  conﬁrm  whether  these  responses  diminished
ver protracted  periods  of time.  Although  we  did
bserve variation  in  IFN-  responses,  we  did  not
bserve  an  association  between  these  responses
nd clinical  manifestation  of  the  disease.  It  is highly
ikely that  this  lack  was  reﬂective  of  the  small  sam-
le size  that  was  used  in  the  ELISPOT  analysis,
nd we  would  suggest  that  our  data  neither  con-
rm nor  deny  the  observations  of  Giambartolomei
t al.  Furthermore,  our  study  lacked  longitudi-
al sampling,  which  would  have  allowed  for  more
ower when  investigating  whether  an  individual’s
esponse declined  over  time.  Ultimately,  these
ests have  not  provided  the  broad  utility  and  sim-
licity that  is  typical  of  serum-based  diagnostics,
nd their  use  in  animal  disease  control  strategies
emains relatively  restricted  to  conﬁrmatory  diag-
ostic testing  and  research  investigations  rather
han high-throughput  screening.  An  analogous  cel-
ular response  test  for  the  diagnosis  of  brucellosis
n humans,  the  Brucella  allergic  skin  test,  was
reviously  used  in  Georgia.  As  scientiﬁc  methods
nd our  understanding  of  the  immune  system  have
mproved  since  the  Brucella  allergic  skin  test  was
ast used,  further  pursuit  of  these  concepts  for
iagnostics  could  be  beneﬁcial.  Currently,  speciﬁc
alidated  diagnostic  tests  for  human  brucellosis
hat rely  on  measurement  of  cellular  immune  effec-
ors are  not  available.  Our  ﬁndings  indicate  that
 strong  adaptive  immune  response  is  measurable
n the  majority  of  patients  and  that  further  inter-
ogation  of  this  response  may  reveal  data  that
re pertinent  to  treatment  outcome  or  prognosis.
oreover, such  tests  may  be  useful  for  predicting
he outcome  of  disease  and/or  treatment  regimens
31].
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Conclusions
This  small  study  demonstrates  persistent  humoral
and cellular  immune  responses  in  patients  with
brucellosis  and  indicates  a  need  for  further  inves-
tigation.  Furthermore,  it  raises  the  possibility  of
using responses  to  Brucella  protein  antigens  (cellu-
lar and  humoral)  as  diagnostic  targets.  In  particular,
the measurement  of  antibody  and  IFN- responses
to BrucellergeneTM protein  epitopes  may  be  worthy
of further  investigation  as  an  alternative  or  adjunct
to current  diagnostics.  Potential  Brucella  vaccine
candidates  could  also  be  assessed  in  these  assays.
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